Kim Chi, MD, professor, University of British Columbia, discusses results of the phase III LATITUDE trial of androgen deprivation therapy with abiraterone acetate plus prednisone (Deltasone) or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
Kim Chi, MD, professor, University of British Columbia, discusses results of the phase III LATITUDE trial of androgen deprivation therapy with abiraterone acetate plus prednisone (Deltasone) or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More